Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 15
August 14 2018
Issue Cover

Table of Contents

DRUG ADVANCES

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
Clinical Trials & Observations
Samantha M. Jaglowski,Bruce R. Blazar
View Articletitled, How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

EXCEPTIONAL CASE REPORT

Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab
Clinical Trials & Observations
Merve Hasanov,Sergej N. Konoplev,Cristhiam M. Rojas Hernandez
View Articletitled, Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab

STIMULUS REPORTS

Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma
Bethany Mundy-Bosse,Nathan Denlinger,Eric McLaughlin,Nitin Chakravarti,Susan Hwang,Li Chen,Hsiaoyin Charlene Mao,David Kline,Youssef Youssef,Rebecca Kohnken,Dean Anthony Lee,Gerard Lozanski,Aharon G. Freud,Pierluigi Porcu,Basem William,Michael A. Caligiuri,Anjali Mishra
View Articletitled, Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma
Supplemental data
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
Clinical Trials & Observations
Ayalew Tefferi,Maura Nicolosi,Domenico Penna,Mythri Mudireddy,Natasha Szuber,Terra L. Lasho,Curtis A. Hanson,Rhett P. Ketterling,Naseema Gangat,Animesh D. Pardanani
View Articletitled, Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels

REVIEW ARTICLE

Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment
Clinical Trials & Observations
George E. Georges,Kris Doney,Rainer Storb
View Articletitled, Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Clinical Trials & Observations
Lili Aslostovar,Allison L. Boyd,Mohammed Almakadi,Tony J. Collins,Darryl P. Leong,Rommel G. Tirona,Richard B. Kim,Jim A. Julian,Anargyros Xenocostas,Brian Leber,Mark N. Levine,Ronan Foley,Mickie Bhatia
View Articletitled, A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Supplemental data
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
Clinical Trials & Observations
Ahmed A. Daak,Carlton D. Dampier,Beng Fuh,Julie Kanter,Ofelia A. Alvarez,L. Vandy Black,Melissa A. McNaull,Michael U. Callaghan,Alex George,Lynne Neumayr,Lee M. Hilliard,Fredrick Sancilio,Adrian L. Rabinowicz,Matthew M. Heeney
View Articletitled, Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency
David Buchbinder,Matthew J. Smith,Misako Kawahara,Morton J. Cowan,Jeffrey S. Buzby,Roshini S. Abraham
View Articletitled, Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency
Supplemental data
CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas
Kieu-Suong Le,Patricia Amé-Thomas,Karin Tarte,Françoise Gondois-Rey,Samuel Granjeaud,Florence Orlanducci,Etienne D. Foucher,Florence Broussais,Reda Bouabdallah,Thierry Fest,Dominique Leroux,Sapna Yadavilli,Patrick A. Mayes,Luc Xerri,Daniel Olive
View Articletitled, CXCR5 and ICOS expression identifies a CD8 T-cell subset with T<sub>FH</sub> features in Hodgkin lymphomas
Supplemental data
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
Shahrzad Jalali,Tammy Price-Troska,Jonas Paludo,Jose Villasboas,Hyo-Jin Kim,Zhi-Zhang Yang,Anne J. Novak,Stephen M. Ansell
View Articletitled, Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

LYMPHOID NEOPLASIA

CD40L/IL-4–stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM
Larissa Lezina,Ruth V. Spriggs,Daniel Beck,Carolyn Jones,Kate M. Dudek,Aleksandra Bzura,George D. D. Jones,Graham Packham,Anne E. Willis,Simon D. Wagner
View Articletitled, CD40L/IL-4–stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM
Supplemental data

MYELOID NEOPLASIA

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
Clinical Trials & Observations
Sanam Loghavi,Dawen Sui,Peng Wei,Guillermo Garcia-Manero,Sherry Pierce,Mark J. Routbort,Elias J. Jabbour,Naveen Pemmaraju,Rashmi Kanagal-Shamanna,H. Deniz Gur,Shimin Hu,Zhuang Zuo,L. Jeffrey Medeiros,Hagop M. Kantarjian,Joseph D. Khoury
View Articletitled, Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
Supplemental data
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
James I. Barnes,Vasu Divi,Adrian Begaye,Russell Wong,Steven Coutre,Douglas K. Owens,Jeremy D. Goldhaber-Fiebert
View Articletitled, Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production
Soe Soe Htwe,Hidenori Wake,Keyue Liu,Kiyoshi Teshigawara,Barbara S. Stonestreet,Yow-Pin Lim,Masahiro Nishibori
View Articletitled, Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Mechanisms of establishment and functional significance of DNA demethylation during erythroid differentiation
Boris Bartholdy,Julien Lajugie,Zi Yan,Shouping Zhang,Rituparna Mukhopadhyay,John M. Greally,Masako Suzuki,Eric E. Bouhassira
View Articletitled, Mechanisms of establishment and functional significance of DNA demethylation during erythroid differentiation
Supplemental data
Characterization of Tfrc-mutant mice with microcytic phenotypes
Ashlee J. Conway,Fiona C. Brown,Gerhard Rank,Benjamin T. Kile,Craig J. Morton,Stephen M. Jane,David J. Curtis
View Articletitled, Characterization of <em>Tfrc</em>-mutant mice with microcytic phenotypes
Elevated ecto-5′-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease
Hong Liu,Morayo Adebiyi,Rong Rong Liu,Anren Song,Jeanne Manalo,Yuan Edward Wen,Alexander Q. Wen,Tingting Weng,Junsuk Ko,Modupe Idowu,Rodney E. Kellems,Holger K. Eltzschig,Michael R. Blackburn,Harinder S. Juneja,Yang Xia
View Articletitled, Elevated ecto-5′-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease
Supplemental data
Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development
Kim Vanuytsel,Taylor Matte,Amy Leung,Zaw Htut Naing,Tasha Morrison,David H. K. Chui,Martin H. Steinberg,George J. Murphy
View Articletitled, Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development
Supplemental data

THROMBOSIS AND HEMOSTASIS

Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis
Manasa K. Nayak,Nirav Dhanesha,Prakash Doddapattar,Omar Rodriguez,Vijay K. Sonkar,Sanjana Dayal,Anil K. Chauhan
View Articletitled, Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis
Supplemental data

TRANSFUSION MEDICINE

The molecular genetic background leading to the formation of the human erythroid-specific Xga/CD99 blood groups
Chih-Chun Yeh,Ching-Jin Chang,Yuh-Ching Twu,Chen-Chung Chu,Bi-Shan Liu,Ji-Ting Huang,Shu-Ting Hung,Yung-Syu Chan,Yi-Jui Tsai,Sheng-Wei Lin,Marie Lin,Lung-Chih Yu
View Articletitled, The molecular genetic background leading to the formation of the human erythroid-specific Xg<sup>a</sup>/CD99 blood groups
Supplemental data

TRANSPLANTATION

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Clinical Trials & Observations
Shernan G. Holtan,Todd E. DeFor,Angela Panoskaltsis-Mortari,Nandita Khera,John E. Levine,Mary E. D. Flowers,Stephanie J. Lee,Yoshihiro Inamoto,George L. Chen,Sebastian Mayer,Mukta Arora,Jeanne Palmer,Corey S. Cutler,Sally Arai,Aleksandr Lazaryan,Laura F. Newell,Madan H. Jagasia,Iskra Pusic,William A. Wood,Anne S. Renteria,Gregory Yanik,William J. Hogan,Elizabeth Hexner,Francis Ayuk,Ernst Holler,Udomsak Bunworasate,Yvonne A. Efebera,James L. M. Ferrara,Joseph Pidala,Alan Howard,Juan Wu,Javier Bolaños-Meade,Vincent Ho,Amin Alousi,Bruce R. Blazar,Daniel J. Weisdorf,Margaret L. MacMillan
View Articletitled, Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Supplemental data
Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation
Yoshihiro Inamoto,Tomohiro Matsuda,Ken Tabuchi,Saiko Kurosawa,Hideki Nakasone,Hisakazu Nishimori,Satoshi Yamasaki,Noriko Doki,Koji Iwato,Takehiko Mori,Satoshi Takahashi,Hiromasa Yabe,Akio Kohno,Hirohisa Nakamae,Toru Sakura,Hisako Hashimoto,Junichi Sugita,Hiroatsu Ago,Takahiro Fukuda,Tatsuo Ichinohe,Yoshiko Atsuta,Takuya Yamashita,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group,on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group
View Articletitled, Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation

ERRATA

Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;1(24):2295-2301.
View Articletitled, Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? <em>Blood Adv.</em> 2017;1(24):2295-2301.
Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2(12):1495-1509.
View Articletitled, Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. <em>Blood Adv.</em> 2018;2(12):1495-1509.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Plots illustrating changes in chromatin during differentiation from hematopoietic stem and progenitor cells (HSPCs) to erythroblasts. Promoters silenced in erythroblasts and promoters silent in both HSPCs and erythroblasts exhibit much more dramatic chromatin changes than promoters activated in erythroblasts. See the article by Bartholdy et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.
Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals